All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Zipalertinib Plus Chemotherapy Moves to Phase 3 Study in EGFR Exon 20 Insertion+ NSCLC

August 4th 2023

The safety and efficacy of zipalertinib plus platinum-based chemotherapy will be compared with platinum-based chemotherapy alone in patients with treatment-naïve, locally advanced or metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations in the phase 3 REZILIENT3 trial.

FDA Issues CRL to BLA Resubmission for Remestemcel-L in Pediatric Steroid-Refractory aGVHD

August 4th 2023

The FDA has released a complete response letter to its biologics license application resubmission, indicating that it needs more data to support approval for remestemcel-L for the treatment of pediatric patients with steroid-refractory acute graft-vs-host disease.

Second-Line Trastuzumab Plus Ramucirumab/Paclitaxel Elicits Activity in HER2+ Gastric/GEJ Cancer

August 4th 2023

Trastuzumab plus ramucirumab and paclitaxel yielded promising efficacy and a manageable safety profile among patients with previously treated HER2-positive advanced gastric/gastroesophageal junction cancer.

Selpercatinib Meets PFS End Point in Newly Diagnosed Advanced or Metastatic RET+ NSCLC

August 4th 2023

Selpercatinib significantly improved progression-free survival vs platinum-based chemotherapy plus pemetrexed and pembrolizumab in patients with advanced or metastatic non–small cell lung cancer harboring RET fusions.

BMS-986158–Based Combos May Provide Another Viable Treatment Approach in Myelofibrosis

August 4th 2023

Haifa Kathrin Al-Ali, MD, provides background on the phase 1/2 study of BMS-986158, presents initial efficacy and safety data from the study, and discusses her hope that novel combination regimens like these could achieve the challenging goal of disease modification in myelofibrosis in the future.

Rutgers Cancer Institute of New Jersey Receives Grants to Support Ongoing Oncology Research

August 4th 2023

Grants totaling $1.5 million have been awarded by the New Jersey Commission on Cancer Research to several investigators at Rutgers Cancer Institute of New Jersey, the state’s only National Cancer Institute-designated Comprehensive Cancer Center together with RWJBarnabas Health.

Stereotactic Ablative Body Radiotherapy Yields Long-Term Disease Control in Lung Oligometastases Regardless of Fractionation Schedule

August 4th 2023

Single-fraction stereotactic ablative body radiotherapy generated overall survival outcomes comparable to those achieved with multifraction SABR in patients with lung oligometastases.

Global Consensus-Finding Meeting Aims to Improve the Management of Chondrosarcoma Complications

August 4th 2023

R. Lor Randall, MD, FACS, provides details about the 2024 Birmingham Orthopedic Oncology Meeting and its main topic of discussion, explains the rationale for its inception, and emphasizes the importance of this meeting for orthopedic oncologists treating chondrosarcoma.

FDA Grants Orphan Drug Designation to ABM-1310 for BRAF V600–Mutant Glioblastoma

August 3rd 2023

The FDA has granted an orphan drug designation to ABM-1310 for the treatment of patients with BRAF V600–mutant glioblastoma.

CD22-Targeted CAR T Cells Elicit Responses With Acceptable Safety in Heavily Pretreated LBCL

August 3rd 2023

Matthew Frank, MD, PhD, discusses the rationale for evaluating CD22 CAR T cells in heavily pretreated patients with large B-cell lymphoma, important safety and efficacy data with this approach, next steps for this research, and how continued efforts may shed needed light on sequencing in this space.

Finding Fulfillment in Research and Patient Care

August 3rd 2023

Stephen T Magill, MD, PhD, details his inspirations behind entering not just the neuro-oncology and surgical treatment field, but also the arena of meningioma care and research; provides topline advice for current fellows looking to enter this field; and details current and ongoing research in this space taking place at Northwestern Medicine.

Stereotactic Radiation Strategies May Bolster RCC Multi-Modality Management Efforts

August 3rd 2023

Raquibul Hannan, MD, PhD, discusses the benefits of using stereotactic radiation in patients with localized RCC who are unfit for surgery, research findings indicating improved outcomes in patients who received radiation for metastatic disease, and how this radiation technique may work in concert with systemic therapy.

Data With Novel Agents Prompt Treatment Sequencing Discussions in MCL and CLL

August 3rd 2023

Catherine C. Coombs, MD, and Alexey Danilov, MD, PhD, moderate a discussion on the role and sequencing of BTK inhibitors, venetoclax-based regimens, and CAR T-cell therapy in mantle cell lymphoma and chronic lymphocytic leukemia.

Investigation of Ubamatamab With or Without Cemiplimab Continues in Recurrent Ovarian Cancer

August 3rd 2023

The preliminary efficacy, safety, and optimal dose of the MUC16xCD3 bispecific antibody ubamatamab alone or in combination with cemiplimab-rwlc continues to be explored in patients with advanced platinum-resistant ovarian cancer in the phase 2 portion of an ongoing, first-in-human, phase 1/2 study.

Batiraxcept Plus Paclitaxel Misses PFS End Point in Platinum-Resistant Ovarian Cancer

August 3rd 2023

The addition of batiraxcept to paclitaxel did not significantly improve progression-free survival compared with paclitaxel alone in a prespecified subset of patients with platinum-resistant ovarian cancer who were not previously exposed to bevacizumab, missing the primary end point of the phase 3 AXLerate-OC trial.

MD Anderson Names Christopher Flowers, MD, Division Head of Cancer Medicine

August 3rd 2023

The University of Texas MD Anderson Cancer Center today announced that Christopher Flowers, MD, an internationally recognized physician-scientist and leader in oncology, has been selected as Division Head of Cancer Medicine after a competitive national search.

Gilteritinib/Chemotherapy Combination Safe and Effective in Newly Diagnosed AML

August 3rd 2023

The addition of the type 1 FLT3 inhibitor gilteritinib to induction and consolidation chemotherapy, followed by maintenance gilteritinib monotherapy, was safe and tolerable with promising initial efficacy in patients with newly diagnosed acute myeloid leukemia.

Further Research May Delineate Immunotherapy Resistance Mechanisms in Lung Cancer

August 2nd 2023

Solange Peters, MD, PhD, discusses the successes and shortcomings of immunotherapy in patients with lung cancer; current challenges with defining resistance mechanisms to immunotherapy in this disease; and the potential applications of circulating tumor DNA monitoring in the early and metastatic disease settings.

Intravenous PRGN-3005 Plus Lymphodepletion Shows Early Promise in Ovarian Cancer

August 2nd 2023

Mary “Nora” Disis, MD, expands on key findings from the phase 1/1b study of PRGN-3005, discusses next steps for the trial, and explains how this research aids efforts to effectively utilize CAR T-cell therapy in ovarian cancer and other solid tumors.

Time to Treatment Initiation Affected by Demographics, Socioeconomics in Solid Tumors

August 2nd 2023

Delays in time to treatment initiation may be associated with demographic and socioeconomic disparities, with care coordination, clinical, and socioeconomic factors representing potential predictors of TTI, according to findings from a retrospective cohort study published in JCO Oncology Practice.